Egetis Therapeutics AB (publ) (STO:EGTX)

Market Cap	2.02B -8.1%
Revenue (ttm)	55.40M -18.4%
Net Income	-333.30M
EPS	-0.93
Shares Out	395.16M
PE Ratio	n/a
Forward PE	21.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	747,202
Average Volume	782,727
Open	5.11
Previous Close	5.12
Day's Range	5.07 - 5.25
52-Week Range	3.03 - 7.07
Beta	1.13
RSI	54.76
Earnings Date	Feb 26, 2026

About Egetis Therapeutics AB

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company’s products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment. The company was ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 40
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EGTX

Financial Performance

In 2024, Egetis Therapeutics AB's revenue was 46.10 million, a decrease of -19.97% compared to the previous year's 57.60 million. Losses were -343.60 million, 5.11% more than in 2023.